FREE SHIPPING over $40
OVER 10000 FIVE-STAR REVIEWS
5% OFF ALL SUBSCRIPTIONS
100% HAPPINESS GUARANTEE
Analyze Diet
0
Journal of virology2000; 74(2); 892-898; doi: 10.1128/jvi.74.2.892-898.2000

Interactions between equine cyclin T1, Tat, and TAR are disrupted by a leucine-to-valine substitution found in human cyclin T1.

Abstract: Transcriptional transactivators (Tat) from human immunodeficiency and equine infectious anemia viruses (HIV and EIAV) interact with their transactivation response elements (TAR) to increase the rates of viral transcription. Whereas the human cyclin T1 is required for the binding of Tat to TAR from HIV, it is unknown how Tat from EIAV interacts with its TAR. Furthermore, Tat from EIAV functions in equine and canine cells but not in human cells. In this study, we present sequences of cyclins T1 from horse and dog and demonstrate that their N-terminal 300 residues rescue the transactivation of Tat from EIAV in human cells. Although human and equine cyclins T1 bind to this Tat, only the equine cyclin T1 supports the binding of Tat to TAR from EIAV. Finally, a reciprocal exchange of the valine for the leucine at position 29 in human and equine cyclins T1, respectively, renders the human cyclin T1 active and the equine cyclin T1 inactive for Tat transactivation from EIAV. Thus, the collaboration between a specific cyclin T1 and Tat for their high-affinity interaction with TAR is a common theme of lentiviral transactivation.
Get Full Text
Publication Date: 2000-01-07 PubMed ID: 10623752PubMed Central: PMC111610DOI: 10.1128/jvi.74.2.892-898.2000Google Scholar: Lookup
The Equine Research Bank provides access to a large database of publicly available scientific literature. Inclusion in the Research Bank does not imply endorsement of study methods or findings by Mad Barn.
LinkedInCopy
  • Journal Article
  • Research Support
  • Non-U.S. Gov't

Summary

This research summary has been generated with artificial intelligence and may contain errors and omissions. Refer to the original study to confirm details provided. Submit correction.

The research investigates how the transcriptional transactivator proteins (Tat) found in HIV and equine infectious anemia viruses (EIAV) interact with certain cyclins to improve the rate of viral transcription. The study reveals that a small mutation, changing leucine to valine, can swap the functionality of human and equine cyclin T1 in supporting Tat transactivation from EIAV.

Objective and Background of the Study

  • The research aims at understanding the interaction dynamics between Transcriptional transactivators (Tat), found in both Equine Infectious Anemia Viruses (EIAV) and the Human Immunodeficiency Virus (HIV), with their respective Transactivation Response elements (TAR).
  • Prior to this study, it was known that human cyclin T1 is essential for the binding of Tat to TAR in HIV. However, the exact method by which Tat from EIAV interacts with its TAR was not known.
  • The study also aimed to inspect why Tat from EIAV performs in equine and canine cells, but fails to function in human cells.

Methodology and Findings

  • The research presented sequences of cyclins T1 from horses and dogs, demonstrating that their N-terminal 300 residues can restore the transactivation capability of Tat from EIAV in human cells.
  • While both human and equine cyclins T1 can bind to Tat from EIAV, only equine cyclin T1 supports the binding of Tat to TAR from EIAV.
  • An intriguing finding of the study was that exchanging a valine for a leucine at position 29 in human and equine cyclins T1 would swap their functionalities. This means the human cyclin T1 would become active and the equine cyclin T1 would become inactive for Tat transactivation from EIAV.

Conclusions

  • The research concluded that the interaction between a specific cyclin T1 and Tat aids their high-affinity interaction with TAR, a common phenomenon observed in lentiviral transactivation.
  • Most significantly, the study discovered that a small protein alteration could drastically influence viral transcription processes, thereby opening up potential avenues for the development of new antiviral strategies.

Cite This Article

APA
Taube R, Fujinaga K, Irwin D, Wimmer J, Geyer M, Peterlin BM. (2000). Interactions between equine cyclin T1, Tat, and TAR are disrupted by a leucine-to-valine substitution found in human cyclin T1. J Virol, 74(2), 892-898. https://doi.org/10.1128/jvi.74.2.892-898.2000

Publication

Journal of virology
ISSN: 0022-538X
NlmUniqueID: 0113724
Country: United States
Language: English
Volume: 74
Issue: 2
Pages: 892-898

Researcher Affiliations

Taube, R
  • Howard Hughes Medical Institute, Departments of Medicine, Microbiology, and Immunology, University of California at San Francisco, San Francisco, California 94143-0703, USA.
Fujinaga, K
    Irwin, D
      Wimmer, J
        Geyer, M
          Peterlin, B M

            MeSH Terms

            • Amino Acid Sequence
            • Amino Acid Substitution
            • Animals
            • Base Sequence
            • Cyclin T
            • Cyclins / genetics
            • Cyclins / isolation & purification
            • Cyclins / metabolism
            • Dogs
            • Gene Products, tat / genetics
            • Gene Products, tat / metabolism
            • HeLa Cells
            • Horses
            • Humans
            • Infectious Anemia Virus, Equine / genetics
            • Infectious Anemia Virus, Equine / metabolism
            • Leucine / genetics
            • Leucine / metabolism
            • Molecular Sequence Data
            • Recombinant Fusion Proteins / genetics
            • Recombinant Fusion Proteins / isolation & purification
            • Recombinant Fusion Proteins / metabolism
            • Response Elements
            • Sequence Homology, Amino Acid
            • Terminal Repeat Sequences
            • Transcriptional Activation
            • Valine / genetics
            • Valine / metabolism

            References

            This article includes 31 references
            1. Andersen G, Busso D, Poterszman A, Hwang JR, Wurtz JM, Ripp R, Thierry JC, Egly JM, Moras D. The structure of cyclin H: common mode of kinase activation and specific features.. EMBO J 1997 Mar 3;16(5):958-67.
              pmc: PMC1169696pubmed: 9118957doi: 10.1093/emboj/16.5.958google scholar: lookup
            2. Bieniasz PD, Grdina TA, Bogerd HP, Cullen BR. Highly divergent lentiviral Tat proteins activate viral gene expression by a common mechanism.. Mol Cell Biol 1999 Jul;19(7):4592-9.
              pmc: PMC84257pubmed: 10373508doi: 10.1128/mcb.19.7.4592google scholar: lookup
            3. Bieniasz PD, Grdina TA, Bogerd HP, Cullen BR. Recruitment of a protein complex containing Tat and cyclin T1 to TAR governs the species specificity of HIV-1 Tat.. EMBO J 1998 Dec 1;17(23):7056-65.
              pmc: PMC1171053pubmed: 9843510doi: 10.1093/emboj/17.23.7056google scholar: lookup
            4. Carroll R, Martarano L, Derse D. Identification of lentivirus tat functional domains through generation of equine infectious anemia virus/human immunodeficiency virus type 1 tat gene chimeras.. J Virol 1991 Jul;65(7):3460-7.
              pmc: PMC241330pubmed: 1645777doi: 10.1128/jvi.65.7.3460-3467.1991google scholar: lookup
            5. Carroll R, Peterlin BM, Derse D. Inhibition of human immunodeficiency virus type 1 Tat activity by coexpression of heterologous trans activators.. J Virol 1992 Apr;66(4):2000-7.
              pmc: PMC288989pubmed: 1312617doi: 10.1128/jvi.66.4.2000-2007.1992google scholar: lookup
            6. Carvalho M, Derse D. Physical and functional characterization of transcriptional control elements in the equine infectious anemia virus promoter.. J Virol 1993 Apr;67(4):2064-74.
              pmc: PMC240285pubmed: 8383228doi: 10.1128/jvi.67.4.2064-2074.1993google scholar: lookup
            7. Carvalho M, Derse D. Mutational analysis of the equine infectious anemia virus Tat-responsive element.. J Virol 1991 Jul;65(7):3468-74.
              pmc: PMC241331pubmed: 1645778doi: 10.1128/jvi.65.7.3468-3474.1991google scholar: lookup
            8. Cujec TP, Cho H, Maldonado E, Meyer J, Reinberg D, Peterlin BM. The human immunodeficiency virus transactivator Tat interacts with the RNA polymerase II holoenzyme.. Mol Cell Biol 1997 Apr;17(4):1817-23.
              pmc: PMC232028pubmed: 9121429doi: 10.1128/mcb.17.4.1817google scholar: lookup
            9. Cujec TP, Okamoto H, Fujinaga K, Meyer J, Chamberlin H, Morgan DO, Peterlin BM. The HIV transactivator TAT binds to the CDK-activating kinase and activates the phosphorylation of the carboxy-terminal domain of RNA polymerase II.. Genes Dev 1997 Oct 15;11(20):2645-57.
              pmc: PMC316603pubmed: 9334327doi: 10.1101/gad.11.20.2645google scholar: lookup
            10. Derse D, Carroll R, Cavalho M, DaSilva L, Martarano L. Functional topography of lentivirus Tat proteins defined by domain switching. Genetic structure and regulation of HIV New York, N.Y: Raven Press; 1991. pp. 251–261.
            11. Derse D, Newbold SH. Mutagenesis of EIAV TAT reveals structural features essential for transcriptional activation and TAR element recognition.. Virology 1993 Jun;194(2):530-6.
              pubmed: 8389074doi: 10.1006/viro.1993.1291google scholar: lookup
            12. Derse D, Carvalho M, Carroll R, Peterlin BM. A minimal lentivirus Tat.. J Virol 1991 Dec;65(12):7012-5.
              pmc: PMC250818pubmed: 1658392doi: 10.1128/jvi.65.12.7012-7015.1991google scholar: lookup
            13. Derse D, Dorn P, DaSilva L, Martarano L. Structure and expression of the equine infectious anemia virus transcriptional trans-activator (tat).. Dev Biol Stand 1990;72:39-48.
              pubmed: 2178129
            14. Derse D, Dorn PL, Levy L, Stephens RM, Rice NR, Casey JW. Characterization of equine infectious anemia virus long terminal repeat.. J Virol 1987 Mar;61(3):743-7.
              pmc: PMC254015pubmed: 3027401doi: 10.1128/jvi.61.3.743-747.1987google scholar: lookup
            15. Dorn P, DaSilva L, Martarano L, Derse D. Equine infectious anemia virus tat: insights into the structure, function, and evolution of lentivirus trans-activator proteins.. J Virol 1990 Apr;64(4):1616-24.
              pmc: PMC249297pubmed: 2157047doi: 10.1128/jvi.64.4.1616-1624.1990google scholar: lookup
            16. Dorn PL, Derse D. cis- and trans-acting regulation of gene expression of equine infectious anemia virus.. J Virol 1988 Sep;62(9):3522-6.
              pmc: PMC253482pubmed: 2841502doi: 10.1128/jvi.62.9.3522-3526.1988google scholar: lookup
            17. Fujinaga K, Cujec TP, Peng J, Garriga J, Price DH, Graña X, Peterlin BM. The ability of positive transcription elongation factor B to transactivate human immunodeficiency virus transcription depends on a functional kinase domain, cyclin T1, and Tat.. J Virol 1998 Sep;72(9):7154-9.
              pmc: PMC109937pubmed: 9696809doi: 10.1128/jvi.72.9.7154-7159.1998google scholar: lookup
            18. Fujinaga K, Taube R, Wimmer J, Cujec TP, Peterlin BM. Interactions between human cyclin T, Tat, and the transactivation response element (TAR) are disrupted by a cysteine to tyrosine substitution found in mouse cyclin T.. Proc Natl Acad Sci U S A 1999 Feb 16;96(4):1285-90.
              pmc: PMC15455pubmed: 9990016doi: 10.1073/pnas.96.4.1285google scholar: lookup
            19. Garber ME, Wei P, KewalRamani VN, Mayall TP, Herrmann CH, Rice AP, Littman DR, Jones KA. The interaction between HIV-1 Tat and human cyclin T1 requires zinc and a critical cysteine residue that is not conserved in the murine CycT1 protein.. Genes Dev 1998 Nov 15;12(22):3512-27.
              pmc: PMC317238pubmed: 9832504doi: 10.1101/gad.12.22.3512google scholar: lookup
            20. Herrmann CH, Rice AP. Specific interaction of the human immunodeficiency virus Tat proteins with a cellular protein kinase.. Virology 1993 Dec;197(2):601-8.
              pubmed: 8249283doi: 10.1006/viro.1993.1634google scholar: lookup
            21. Ivanov D, Kwak YT, Nee E, Guo J, García-Martínez LF, Gaynor RB. Cyclin T1 domains involved in complex formation with Tat and TAR RNA are critical for tat-activation.. J Mol Biol 1999 Apr 23;288(1):41-56.
              pubmed: 10329125doi: 10.1006/jmbi.1999.2663google scholar: lookup
            22. Jones KA. Taking a new TAK on tat transactivation.. Genes Dev 1997 Oct 15;11(20):2593-9.
              pubmed: 9334323doi: 10.1101/gad.11.20.2593google scholar: lookup
            23. Jones KA, Peterlin BM. Control of RNA initiation and elongation at the HIV-1 promoter.. Annu Rev Biochem 1994;63:717-43.
              pubmed: 7979253doi: 10.1146/annurev.bi.63.070194.003441google scholar: lookup
            24. Kraulis PJ. MOLSCRIPT, a program to produce both detailed and schematic plots of protein structures. J Appl Crystallogr 1991;24:946–950.
            25. Kwak YT, Ivanov D, Guo J, Nee E, Gaynor RB. Role of the human and murine cyclin T proteins in regulating HIV-1 tat-activation.. J Mol Biol 1999 Apr 23;288(1):57-69.
              pubmed: 10329126doi: 10.1006/jmbi.1999.2664google scholar: lookup
            26. Madore SJ, Cullen BR. Genetic analysis of the cofactor requirement for human immunodeficiency virus type 1 Tat function.. J Virol 1993 Jul;67(7):3703-11.
              pmc: PMC237733pubmed: 8389901doi: 10.1128/jvi.67.7.3703-3711.1993google scholar: lookup
            27. Maury W. Regulation of equine infectious anemia virus expression.. J Biomed Sci 1998;5(1):11-23.
              pubmed: 9570509doi: 10.1007/bf02253351google scholar: lookup
            28. Noiman S, Gazit A, Tori O, Sherman L, Miki T, Tronick SR, Yaniv A. Identification of sequences encoding the equine infectious anemia virus tat gene.. Virology 1990 May;176(1):280-8.
              pubmed: 2158694doi: 10.1016/0042-6822(90)90254-ogoogle scholar: lookup
            29. Peitsch MC. ProMod and Swiss-Model: Internet-based tools for automated comparative protein modelling.. Biochem Soc Trans 1996 Feb;24(1):274-9.
              pubmed: 8674685doi: 10.1042/bst0240274google scholar: lookup
            30. Peng J, Zhu Y, Milton JT, Price DH. Identification of multiple cyclin subunits of human P-TEFb.. Genes Dev 1998 Mar 1;12(5):755-62.
              pmc: PMC316581pubmed: 9499409doi: 10.1101/gad.12.5.755google scholar: lookup
            31. Wei P, Garber ME, Fang SM, Fischer WH, Jones KA. A novel CDK9-associated C-type cyclin interacts directly with HIV-1 Tat and mediates its high-affinity, loop-specific binding to TAR RNA.. Cell 1998 Feb 20;92(4):451-62.
              pubmed: 9491887doi: 10.1016/s0092-8674(00)80939-3google scholar: lookup

            Citations

            This article has been cited 18 times.
            1. Zhang X, Li J, Zhang M, Bai B, Ma W, Lin Y, Guo X, Wang XF, Wang X. A Novel, Fully Spliced, Accessory Gene in Equine Lentivirus with Distinct Rev-Responsive Element. J Virol 2022 Sep 28;96(18):e0098622.
              doi: 10.1128/jvi.00986-22pubmed: 36069548google scholar: lookup
            2. Fujinaga K. P-TEFb as A Promising Therapeutic Target. Molecules 2020 Feb 14;25(4).
              doi: 10.3390/molecules25040838pubmed: 32075058google scholar: lookup
            3. Ali I, Ramage H, Boehm D, Dirk LM, Sakane N, Hanada K, Pagans S, Kaehlcke K, Aull K, Weinberger L, Trievel R, Schnoelzer M, Kamada M, Houtz R, Ott M. The HIV-1 Tat Protein Is Monomethylated at Lysine 71 by the Lysine Methyltransferase KMT7. J Biol Chem 2016 Jul 29;291(31):16240-8.
              doi: 10.1074/jbc.M116.735415pubmed: 27235396google scholar: lookup
            4. Pak V, Eifler TT, Jäger S, Krogan NJ, Fujinaga K, Peterlin BM. CDK11 in TREX/THOC Regulates HIV mRNA 3' End Processing. Cell Host Microbe 2015 Nov 11;18(5):560-70.
              doi: 10.1016/j.chom.2015.10.012pubmed: 26567509google scholar: lookup
            5. Tahirov TH, Babayeva ND, Varzavand K, Cooper JJ, Sedore SC, Price DH. Crystal structure of HIV-1 Tat complexed with human P-TEFb. Nature 2010 Jun 10;465(7299):747-51.
              doi: 10.1038/nature09131pubmed: 20535204google scholar: lookup
            6. Zhang B, Montelaro RC. Replication of equine infectious anemia virus in engineered mouse NIH 3T3 cells. J Virol 2009 Feb;83(4):2034-7.
              doi: 10.1128/JVI.01883-08pubmed: 19073738google scholar: lookup
            7. Jadlowsky JK, Nojima M, Schulte A, Geyer M, Okamoto T, Fujinaga K. Dominant negative mutant cyclin T1 proteins inhibit HIV transcription by specifically degrading Tat. Retrovirology 2008 Jul 11;5:63.
              doi: 10.1186/1742-4690-5-63pubmed: 18620576google scholar: lookup
            8. Anand K, Schulte A, Fujinaga K, Scheffzek K, Geyer M. Cyclin box structure of the P-TEFb subunit cyclin T1 derived from a fusion complex with EIAV tat. J Mol Biol 2007 Jul 27;370(5):826-36.
              doi: 10.1016/j.jmb.2007.04.077pubmed: 17540406google scholar: lookup
            9. Baek K, Brown RS, Birrane G, Ladias JA. Crystal structure of human cyclin K, a positive regulator of cyclin-dependent kinase 9. J Mol Biol 2007 Feb 16;366(2):563-73.
              doi: 10.1016/j.jmb.2006.11.057pubmed: 17169370google scholar: lookup
            10. Blazek D, Barboric M, Kohoutek J, Oven I, Peterlin BM. Oligomerization of HEXIM1 via 7SK snRNA and coiled-coil region directs the inhibition of P-TEFb. Nucleic Acids Res 2005;33(22):7000-10.
              doi: 10.1093/nar/gki997pubmed: 16377779google scholar: lookup
            11. Fujinaga K, Irwin D, Huang Y, Taube R, Kurosu T, Peterlin BM. Dynamics of human immunodeficiency virus transcription: P-TEFb phosphorylates RD and dissociates negative effectors from the transactivation response element. Mol Cell Biol 2004 Jan;24(2):787-95.
              doi: 10.1128/MCB.24.2.787-795.2004pubmed: 14701750google scholar: lookup
            12. Fujinaga K, Irwin D, Taube R, Zhang F, Geyer M, Peterlin BM. A minimal chimera of human cyclin T1 and tat binds TAR and activates human immunodeficiency virus transcription in murine cells. J Virol 2002 Dec;76(24):12934-9.
              doi: 10.1128/jvi.76.24.12934-12939.2002pubmed: 12438619google scholar: lookup
            13. Liou LY, Herrmann CH, Rice AP. Transient induction of cyclin T1 during human macrophage differentiation regulates human immunodeficiency virus type 1 Tat transactivation function. J Virol 2002 Nov;76(21):10579-87.
              doi: 10.1128/jvi.76.21.10579-10587.2002pubmed: 12368300google scholar: lookup
            14. Kim YK, Bourgeois CF, Isel C, Churcher MJ, Karn J. Phosphorylation of the RNA polymerase II carboxyl-terminal domain by CDK9 is directly responsible for human immunodeficiency virus type 1 Tat-activated transcriptional elongation. Mol Cell Biol 2002 Jul;22(13):4622-37.
              doi: 10.1128/MCB.22.13.4622-4637.2002pubmed: 12052871google scholar: lookup
            15. Garber ME, Mayall TP, Suess EM, Meisenhelder J, Thompson NE, Jones KA. CDK9 autophosphorylation regulates high-affinity binding of the human immunodeficiency virus type 1 tat-P-TEFb complex to TAR RNA. Mol Cell Biol 2000 Sep;20(18):6958-69.
              doi: 10.1128/MCB.20.18.6958-6969.2000pubmed: 10958691google scholar: lookup
            16. Barboric M, Taube R, Nekrep N, Fujinaga K, Peterlin BM. Binding of Tat to TAR and recruitment of positive transcription elongation factor b occur independently in bovine immunodeficiency virus. J Virol 2000 Jul;74(13):6039-44.
              doi: 10.1128/jvi.74.13.6039-6044.2000pubmed: 10846086google scholar: lookup
            17. Price DH. P-TEFb, a cyclin-dependent kinase controlling elongation by RNA polymerase II. Mol Cell Biol 2000 Apr;20(8):2629-34.
              doi: 10.1128/MCB.20.8.2629-2634.2000pubmed: 10733565google scholar: lookup
            18. Schimmich C, Vabret A, Zientara S, Valle-Casuso JC. Equine Infectious Anemia Virus Cellular Partners Along the Viral Cycle. Viruses 2024 Dec 24;17(1).
              doi: 10.3390/v17010005pubmed: 39861793google scholar: lookup
            Subscribe to our newsletter
            Join 99,780 horse owners like you who receive our email updates on horse health and nutrition.